<p>隨着美國股市面臨人工智能股票的壓力並期待關鍵經濟數據的發佈，投資者密切關注這些因素如何影響更廣泛的市場趨勢。在如此波動的環境中，內部持股比例高的成長型公司往往脱穎而出，因為這表明了與企業關係最密切的人的信心，使它們成為在不確定性中尋求穩定的投資者的有趣選擇。</p>
<h3>美國內部持股比例高的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>超微計算機 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.9%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17.3%</td>
<td>78.5%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.4%</td>
<td>52.7%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>27.1%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們內部持股比例高的快速成長美國公司篩選器中的 204 只股票的完整列表。</p>
<p>讓我們深入探討篩選器中的一些主要選擇。</p>
<h2>Paysign (PAYS)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Paysign, Inc. 提供預付卡項目、患者負擔能力解決方案、數字銀行服務以及針對各個行業的綜合支付處理，市值為 2.9503 億美元。</p>
<p><strong>運營：</strong> Paysign 的收入主要來自其垂直整合的預付卡產品和處理服務提供商，收入為 7488 萬美元。</p>
<p><strong>內部持股比例：</strong> 36.3%</p>
<p><strong>盈利增長預測：</strong> 每年 25.4%。</p>
<p>Paysign 的增長軌跡由預計每年增長 25.42% 的盈利所支撐，超過美國市場的 16.1%。儘管收入增長低於 20%，但仍高於市場平均水平 18.4%。最近的季度結果顯示銷售額和淨收入同比顯著改善，全年收入預計增長近 39%。公司的戰略領導變動旨在增強其生命科學領域的存在，儘管內部交易活動仍然較少。</p>
<ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 Paysign 的表現。</li>
<li>我們編制的估值報告表明，Paysign 當前的價格可能被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c8db4a8d-99e7-4237-9792-3a1d1f3383eb/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c8db4a8d-99e7-4237-9792-3a1d1f3383eb/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 PAYS 盈利和收入增長</p>
<h2>Amneal Pharmaceuticals (AMRX)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Amneal Pharmaceuticals, Inc. 是一家全球生物製藥公司，開發、製造、營銷和分銷仿製藥、注射劑、生物類似藥和特種品牌藥品，市值約為 39.2 億美元。</p>
<p><strong>運營：</strong> 公司的收入部分包括 Avkare（7.0437 億美元）、Specialty（4.8242 億美元）和 Affordable Medicines（17.5 億美元）。</p>
<p><strong>內部持股比例：</strong> 39.2%</p>
<p><strong>盈利增長預測：</strong> 每年 80.1%。</p>
<p>Amneal Pharmaceuticals 作為一家成長型公司，顯示出潛力，內部持股比例顯著，最近獲得 FDA 對關鍵產品如腎上腺素注射劑和硫酸沙丁胺醇吸入氣霧劑的批准，進一步豐富了其呼吸系統產品組合。儘管與同行相比交易價值良好，但預計公司在未來三年內盈利將顯著增長，儘管收入增長預測落後於更廣泛的市場。公司在複雜藥物配方方面的戰略舉措凸顯了其對創新的承諾。</p>
<ul>
<li>點擊這裏訪問我們的完整增長分析報告，以瞭解 Amneal Pharmaceuticals 的動態。</li>
<li>我們的綜合估值報告提出 Amneal Pharmaceuticals 的股價可能低於其財務狀況所能證明的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/de8755ce-faf4-4170-8a24-89d67d81be0e/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/de8755ce-faf4-4170-8a24-89d67d81be0e/chart/earnings-and-revenue-growth"/></p>
<p>截至 2025 年 12 月的 AMRX 盈利和收入增長</p>
<h2>Dingdong (Cayman) (DDL)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Dingdong (Cayman) Limited 作為一家電子商務公司在中國運營，市值約為 4.3933 億美元。</p>
<p><strong>運營：</strong> 該公司主要通過其在線零售部門產生收入，報告為 240.2 億人民幣。</p>
<p><strong>內部持股比例：</strong> 28.6%</p>
<p><strong>盈利增長預測：</strong> 每年 25%。</p>
<p>Dingdong (Cayman) 展示了增長潛力，內部持股比例可觀，與同行相比交易價值良好。儘管收入增長預測為每年 9.1%，落後於美國市場，但預計其盈利在未來三年將顯著增長，年均增長 25%。最近的第三季度結果顯示收入增加，但淨收入和每股收益下降，反映出在擴張努力中維持盈利能力的挑戰。</p>
<ul>
<li>點擊以探索我們在 Dingdong (Cayman) 盈利增長報告中的詳細發現。</li>
<li>我們的估值報告揭示了 Dingdong (Cayman) 的股票可能以折扣價交易的可能性。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a049d724-5af7-453a-a3bd-a419c44708f3/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a049d724-5af7-453a-a3bd-a419c44708f3/chart/ownership-breakdown"/></p>
<p>截至 2025 年 12 月的 DDL 持股結構</p>
<h2>利用機會</h2>
<ul>
<li>點擊開始探索其餘 201 只內部持股比例高的快速成長美國公司的信息。</li>
<li>尋找替代機會？我們發現 13 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</li>
</ul>
<p>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不意圖作為財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</p>
<p>國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是類人型的，而是能夠在 30 分鐘內在任何地方提供 5G、ISR 和雷達的全自動塔。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

AMRX

<p>投資者在市場波動中密切關注內部持股比例高的成長型公司。值得注意的公司包括超級微型計算機（Super Micro Computer）、StubHub Holdings、SES AI、牛電科技（Niu Technologies）、Karman Holdings、Credo Technology、Corcept Therapeutics、Atour Lifestyle、Astera Labs 和 AppLovin。被特別提及的公司有 Paysign、Amneal Pharmaceuticals 和 Dingdong (Cayman)，它們均顯示出顯著的內部持股比例和良好的盈利增長預測。Simply Wall St 提供了詳細的分析，但提醒其評論並非財務建議</p>

<p>As the U.S. stock market grapples with pressures on AI stocks and anticipates key economic data releases, investors are keenly observing how these factors influence broader market trends. In such a volatile environment, growth companies with high insider ownership often stand out as they suggest confidence from those closest to the business, making them intriguing prospects for investors seeking stability amid uncertainty.</p>
<div class="lb-trans"><p>隨着美國股市面臨人工智能股票的壓力並期待關鍵經濟數據的發佈，投資者密切關注這些因素如何影響更廣泛的市場趨勢。在如此波動的環境中，內部持股比例高的成長型公司往往脱穎而出，因為這表明了與企業關係最密切的人的信心，使它們成為在不確定性中尋求穩定的投資者的有趣選擇。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In The United States</h3>
<div class="lb-trans"><h3>美國內部持股比例高的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Super Micro Computer (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.9%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17.3%</td>
<td>78.5%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.4%</td>
<td>52.7%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>27.1%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>超微計算機 (SMCI)</td>
<td>13.9%</td>
<td>50.7%</td>
</tr>
<tr>
<td>StubHub Holdings (STUB)</td>
<td>14.2%</td>
<td>73.9%</td>
</tr>
<tr>
<td>SES AI (SES)</td>
<td>12%</td>
<td>68.9%</td>
</tr>
<tr>
<td>Niu Technologies (NIU)</td>
<td>37.2%</td>
<td>93.7%</td>
</tr>
<tr>
<td>Karman Holdings (KRMN)</td>
<td>17.3%</td>
<td>78.5%</td>
</tr>
<tr>
<td>Credo Technology Group Holding (CRDO)</td>
<td>10.4%</td>
<td>30.7%</td>
</tr>
<tr>
<td>Corcept Therapeutics (CORT)</td>
<td>11.4%</td>
<td>52.7%</td>
</tr>
<tr>
<td>Atour Lifestyle Holdings (ATAT)</td>
<td>18%</td>
<td>24.4%</td>
</tr>
<tr>
<td>Astera Labs (ALAB)</td>
<td>11.7%</td>
<td>29.0%</td>
</tr>
<tr>
<td>AppLovin (APP)</td>
<td>27.4%</td>
<td>27.1%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 204 stocks from our Fast Growing US Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們內部持股比例高的快速成長美國公司篩選器中的 204 只股票的完整列表。</p>
</div><p>Let's dive into some prime choices out of the screener.</p>
<div class="lb-trans"><p>讓我們深入探討篩選器中的一些主要選擇。</p>
</div><h2>Paysign (PAYS)</h2>
<div class="lb-trans"><h2>Paysign (PAYS)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Paysign, Inc. offers prepaid card programs, patient affordability solutions, digital banking services, and integrated payment processing for various sectors with a market cap of $295.03 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Paysign, Inc. 提供預付卡項目、患者負擔能力解決方案、數字銀行服務以及針對各個行業的綜合支付處理，市值為 2.9503 億美元。</p>
</div><p><strong>Operations:</strong> Paysign's revenue primarily comes from its vertically integrated provider of prepaid card products and processing services, generating $74.88 million.</p>
<div class="lb-trans"><p><strong>運營：</strong> Paysign 的收入主要來自其垂直整合的預付卡產品和處理服務提供商，收入為 7488 萬美元。</p>
</div><p><strong>Insider Ownership:</strong> 36.3%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 36.3%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 25.4% p.a.</p>
<div class="lb-trans"><p><strong>盈利增長預測：</strong> 每年 25.4%。</p>
</div><p>Paysign's growth trajectory is underscored by a forecasted earnings increase of 25.42% per year, outpacing the US market's 16.1%. Despite revenue growth being slower than 20%, it surpasses the market average at 18.4%. Recent quarterly results show significant year-over-year improvements in sales and net income, with full-year revenues projected to grow by nearly 39%. The company's strategic leadership changes aim to enhance its life sciences sector presence, though insider trading activity remains minimal.</p>
<div class="lb-trans"><p>Paysign 的增長軌跡由預計每年增長 25.42% 的盈利所支撐，超過美國市場的 16.1%。儘管收入增長低於 20%，但仍高於市場平均水平 18.4%。最近的季度結果顯示銷售額和淨收入同比顯著改善，全年收入預計增長近 39%。公司的戰略領導變動旨在增強其生命科學領域的存在，儘管內部交易活動仍然較少。</p>
</div><ul>
<li>Get an in-depth perspective on Paysign's performance by reading our analyst estimates report here.</li>
<li>The valuation report we've compiled suggests that Paysign's current price could be inflated.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解 Paysign 的表現。</li>
<li>我們編制的估值報告表明，Paysign 當前的價格可能被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/c8db4a8d-99e7-4237-9792-3a1d1f3383eb/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/c8db4a8d-99e7-4237-9792-3a1d1f3383eb/chart/earnings-and-revenue-growth"/></p>
<p>PAYS Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 PAYS 盈利和收入增長</p>
</div><h2>Amneal Pharmaceuticals (AMRX)</h2>
<div class="lb-trans"><h2>Amneal Pharmaceuticals (AMRX)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Amneal Pharmaceuticals, Inc. is a global biopharmaceutical company that develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide with a market cap of approximately $3.92 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Amneal Pharmaceuticals, Inc. 是一家全球生物製藥公司，開發、製造、營銷和分銷仿製藥、注射劑、生物類似藥和特種品牌藥品，市值約為 39.2 億美元。</p>
</div><p><strong>Operations:</strong> The company's revenue segments include Avkare at $704.37 million, Specialty at $482.42 million, and Affordable Medicines at $1.75 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入部分包括 Avkare（7.0437 億美元）、Specialty（4.8242 億美元）和 Affordable Medicines（17.5 億美元）。</p>
</div><p><strong>Insider Ownership:</strong> 39.2%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 39.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 80.1% p.a.</p>
<div class="lb-trans"><p><strong>盈利增長預測：</strong> 每年 80.1%。</p>
</div><p>Amneal Pharmaceuticals shows potential as a growth company with significant insider ownership, highlighted by its recent FDA approvals for key products like epinephrine injections and albuterol sulfate inhalation aerosol, adding to its expanding respiratory portfolio. While trading at a good value compared to peers, the company's earnings are expected to grow significantly over the next three years, despite revenue growth forecasts lagging behind the broader market. The company's strategic moves in complex drug formulations underscore its commitment to innovation.</p>
<div class="lb-trans"><p>Amneal Pharmaceuticals 作為一家成長型公司，顯示出潛力，內部持股比例顯著，最近獲得 FDA 對關鍵產品如腎上腺素注射劑和硫酸沙丁胺醇吸入氣霧劑的批准，進一步豐富了其呼吸系統產品組合。儘管與同行相比交易價值良好，但預計公司在未來三年內盈利將顯著增長，儘管收入增長預測落後於更廣泛的市場。公司在複雜藥物配方方面的戰略舉措凸顯了其對創新的承諾。</p>
</div><ul>
<li>Click here and access our complete growth analysis report to understand the dynamics of Amneal Pharmaceuticals.</li>
<li>Our comprehensive valuation report raises the possibility that Amneal Pharmaceuticals is priced lower than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊這裏訪問我們的完整增長分析報告，以瞭解 Amneal Pharmaceuticals 的動態。</li>
<li>我們的綜合估值報告提出 Amneal Pharmaceuticals 的股價可能低於其財務狀況所能證明的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/de8755ce-faf4-4170-8a24-89d67d81be0e/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/de8755ce-faf4-4170-8a24-89d67d81be0e/chart/earnings-and-revenue-growth"/></p>
<p>AMRX Earnings and Revenue Growth as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 AMRX 盈利和收入增長</p>
</div><h2>Dingdong (Cayman) (DDL)</h2>
<div class="lb-trans"><h2>Dingdong (Cayman) (DDL)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Dingdong (Cayman) Limited operates as an e-commerce company in China with a market cap of approximately $439.33 million.</p>
<div class="lb-trans"><p><strong>概述：</strong> Dingdong (Cayman) Limited 作為一家電子商務公司在中國運營，市值約為 4.3933 億美元。</p>
</div><p><strong>Operations:</strong> The company generates revenue primarily through its online retail segment, which reported CN¥24.02 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司主要通過其在線零售部門產生收入，報告為 240.2 億人民幣。</p>
</div><p><strong>Insider Ownership:</strong> 28.6%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 28.6%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 25% p.a.</p>
<div class="lb-trans"><p><strong>盈利增長預測：</strong> 每年 25%。</p>
</div><p>Dingdong (Cayman) demonstrates growth potential with substantial insider ownership, trading at a good value compared to peers. Despite revenue growth forecasts of 9.1% per year lagging behind the US market, its earnings are expected to grow significantly at 25% annually over the next three years. Recent Q3 results showed increased revenue but decreased net income and earnings per share, reflecting challenges in maintaining profitability amidst expansion efforts.</p>
<div class="lb-trans"><p>Dingdong (Cayman) 展示了增長潛力，內部持股比例可觀，與同行相比交易價值良好。儘管收入增長預測為每年 9.1%，落後於美國市場，但預計其盈利在未來三年將顯著增長，年均增長 25%。最近的第三季度結果顯示收入增加，但淨收入和每股收益下降，反映出在擴張努力中維持盈利能力的挑戰。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Dingdong (Cayman)'s earnings growth report.</li>
<li>Our valuation report unveils the possibility Dingdong (Cayman)'s shares may be trading at a discount.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊以探索我們在 Dingdong (Cayman) 盈利增長報告中的詳細發現。</li>
<li>我們的估值報告揭示了 Dingdong (Cayman) 的股票可能以折扣價交易的可能性。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/a049d724-5af7-453a-a3bd-a419c44708f3/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/a049d724-5af7-453a-a3bd-a419c44708f3/chart/ownership-breakdown"/></p>
<p>DDL Ownership Breakdown as at Dec 2025</p>
<div class="lb-trans"><p>截至 2025 年 12 月的 DDL 持股結構</p>
</div><h2>Taking Advantage</h2>
<div class="lb-trans"><h2>利用機會</h2>
</div><ul>
<li>Click through to start exploring the rest of the 201 Fast Growing US Companies With High Insider Ownership now.</li>
<li>Looking For Alternative Opportunities? We've found 13 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊開始探索其餘 201 只內部持股比例高的快速成長美國公司的信息。</li>
<li>尋找替代機會？我們發現 13 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不意圖作為財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的，而是能夠在 30 分鐘內在任何地方提供 5G、ISR 和雷達的全自動塔。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

三家受到內部人士青睞的成長型公司值得關注